Does positive criterium for p53 immunohistochemical analysis in the confirmation of Barrett's dysplasia make difference?;O critério de positividade para a análise imunoistoquímica da p53 na confirmação da displasia do esôfago de barrett faz diferença?

Arquivos de Gastroenterologia

Volumn 42, Issue 4, 2005, Pages 233-238

  Lopes, César Vivian ^a,b,f   Pereira Lima, Júlio C ^a,c   Hartmann, Antônio Atalíbio ^a,d   Tonelotto, Eunice ^a,e   Salgado, Karina ^a,c  

^a Fund Riograndense Univ G   (Brazil)

^b UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^c UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^d Department of Pulmonology   (Brazil)

^e Fundação Riograndense Universitária de Gastroenterologia

^f Departamento de Patologia da FFFCMPA ^*  (Brazil)

Author keywords

Barrett esophagus; Protein p53

Indexed keywords

ALCIAN BLUE; EOSIN; FORMALDEHYDE; HEMATOXYLIN; PARAFFIN; PROTEIN P53; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; BARRETT ESOPHAGUS; CELL CULTURE; CELL NUCLEUS; CLINICAL ARTICLE; ENDOSCOPIC BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOLOGIST; PATIENT; PROTEIN ANALYSIS; STAINING; TISSUE SECTION;

EID: 32544437373     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/s0004-28032005000400008     Document Type: Article

References (34)

1. Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc 1999;50:23-6.
2. Baas IO, Mulder J-WR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
3. Bian Y-S, Osterheld M-C, Bosman FT, Benhattar J, Fontolliet C. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol 2001;14:397-403.
4. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am 1997;26:487-94.
5. Casson AG, Manolopoulos B, Troster M, Kerkvliet N, O'Malley F, Inculet R, Finley R, Roth JA. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Am J Surg 1994;167:52-7.
6. Cross SS. Grading and scoring in histopathology. Histopathology 1998; 33:99-106.
7. Daly JM, Fry WA, Little AG, Winchester DP, Mckee RF, Stewart AK, Fremgen AM. Esophageal cancer: results of an American College of Surgeons patient care evaluation study. J Am Coll Surg 2000;190:548-59.
8. DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. Ann Surg 2000;231:303-21.
9. Fitzpatrick FA. Inflammation, carcinogenesis and cancer. Int Immunopharmacol 2001;1:1651-67.
10. Geboes K, Van Eyken P. The diagnosis of dysplasia and malignancy in Barrett's oesophagus. Histopathology 2000;37:99-107.
11. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? - revisited! J Pathol 1994;172:1-4.
12. Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut 1994;35:764-8.
13. Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, Harris CC. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 2003;100:143-8.
14. Hulscher JBF, Haringsma J, BenraadT J, Offerhaus GJA, Kate FJW, Baak JPA, Tytgat GNJ, Van Lanschot JJB. Comprehensive Cancer Centre Amsterdam Barrett Advisory Committee: first results. Neth J Med 2001;58:3-8.
15. Illueca C, Llombart-Bosch A, Ferrando Cucarella J. Factores pronósticos en el esófago de Barrett: estudio inmunohistoquímico y morfométrico de 120 casos. Rev Esp Enferm Dig 2000;92:726-31.
16. Ireland AP, Clark GWB, DeMeester TR. Barrett's esophagus: the significance of p53 in clinical practice. Ann Surg 1997;225:17-30.
17. Krishnadath KK, Tilanus HW, Blankenstein MV, Bosman FT, Mulder AH. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. J Pathol 1995;175:175-80.
18. Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clin Proc 2001;76:438-46.
19. Kubba AK, Poole NA, Watson A. Role of p53 assessment in management of Barrett's esophagus. Dig Dis Sci 1999;44:659-67.
20. Lopes CV, Pereira-Lima JC, Hartmann AA, Tonelotto E. Reprodutibilidade no diagnóstico histopatológico do esôfago de Barrett na presença de metaplasia intestinal focal em biópsias endoscópicas. GED Gastroenterol Endosc Dig 2004;23:47-52.
21. Lopes CV, Pereira-Lima JC, Hartmann AA, Tonelotto E, Salgado K. Displasia no esôfago de Barrett - concordância intra e interobservador no diagnóstico histopatológico. Arq Gastroenterol 2004;41:5-9.
22. Lopes CV, Pereira-Lima JC, Hartmann AA. Correlation between alcian blue-periodic acid-schiff stain and immunohistochemical expression of mucin 2 in Barrett,s oesophagus. Histopathology 2004;45:198-9.
23. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004;64:1561-9.
24. Mighell AJ, Hume WJ, Robinson PA. An overview of the complexities and subtleties of immunohistochemistry. Oral Dis 1998;4:217-23.
25. Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Toledano AY, Shyr Y, Washington K. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-78.
26. Morales TG, Sampliner RE. Barrett's esophagus: update on screening, surveillance, and treatment. Arch Intern Med 1999;159:1411-6.
27. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus. Am J Gastroenterol 1999;94:2037-42.
28. Polkowski W, Baak JPA, Van Lanschot JJB, Meijer GA, Schuurmans LT, Ten Kate FJW, Obertop H, Offerhaus GJA. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation. J Pathol 1998;184:161-8.
29. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
30. Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003;13:369-97.
31. Sampliner RE, The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
32. Symmans PJ, Linehan JM, Brito MJ, Filipe MI. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol 1994;173:221-6.
33. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999;94:3413-9.
34. Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol 1998;152:287-94.